Science & Technology
Science and Technology
Science and Technology
Tue, June 1, 2010
Mon, May 31, 2010
Sun, May 30, 2010
Fri, May 28, 2010 Zacks' Voice of the People highlights opportunities with Targeted Genetics and Aastrom Biosciences
CHICAGO--([ BUSINESS WIRE ])--Zacks highlights commentary from People and Picks Trader aAndrewGreenBulla.
For more Voice of the People, visit [ http://at.zacks.com/?id=5851 ]
Featured Post
Biotech Calendar: Key Dates for Wild Pennies
When the chaos in Europe settles down, these wild pennies with key catalysts in the near-term may outperform the market:
May 30
Targeted Genetics Corporation (OTC: [ TGEN ])
Although major indices in the U.S. have lost more than 10% since Aprila™s high, TGEN still has 50% gains in the same period.
On Apr 28, 2010, TGEN announced that its licensing partner, Celladon Corporation, had reported that the companya™s first Phase II trial with MYDICAR® for the treatment of advanced heart failure had met primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.
The full data from Celladon's clinical trial will be presented at the Heart Failure Congress 2010 on May 30, 2010, and Celladon also will uncover its plans for future development of MYDICAR. TGEN could receive multiple milestone payments totaling up to $20 million plus a 10% royalty on commercial sales of MYDICAR.
Compared with MYDICARa™s future value, TGENa™s 6.61 million market capital looks attractive even in the bear market.
June 11
Aastrom Biosciences, Inc. (Nasdaq: [ ASTM ])
ASTM will present positive interim results from the company's U.S. Phase 2b trial designated RESTORE-CLI at this year's Vascular Annual Meeting(R) of the Society for Vascular Surgery on June 11 in Boston, MA.
RESTORE-CLI is the largest double-blind, randomized cell therapy study to be conducted for critical limb ischemia or CLI, the end-stage of peripheral arterial disease.
As of March 31, 2010, the company had $22.8 million in cash and cash equivalents and short-term investments.
My take is pretty simple for this one: 3 promising drug candidates in late-stage clinical trials + one orphan drug designation + $22.8 million what is enough for at least next 12 month cash utilization according to $1.4 monthly burn rate > $39 million market capital.
So why ASTM is still around 52 weeks low when it is financially stable and good news kept coming out in the past few weeks? A bear market cannot explain for this anymore.
Maybe ASTM needs some spotlight besides good data, and I believe that Boston is the right place to go.
About the Zacks Community
In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. Each user is scored on the accuracy of his or her picks, and top users are rewarded with free products from Zacks. Registration is free. To learn more about People And Picks, visit [ http://at.zacks.com/?id=5957 ]
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to [ http://at.zacks.com/?id=5958 ].
Follow us on Twitter: [ http://twitter.com/ZacksInvestment ]
Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
